AGRP and obesity due to melanocortin 4 receptor deficiency: In females, we did not observe any significant difference in response to either Agrp or an HFD, which is similar to the clinical reports that there is no association between obesity and melanoma risk in females (Dobbins et al., 2013; Sergentanis et al., 2013).